We just need your email, then we'll add you to the list!
Cannabis use for common conditions: Research, fact and fiction
Nov 5, 2022 - McMaster University - 55 minutes
The Bottom Line
Medical cannabis has been legal in Canada for more than two decades, but its use has dramatically increased in the last few years, and, with the legalization of recreational cannabis in 2018, there has been an increased interest in therapeutic uses for cannabis. In this webinar recording, Drs. Jason Busse and James MacKillop discuss what the latest research says about the potential for cannabis to help with common medical conditions.
Learn the answers to the following questions:
2:32 What does the Michael G. Degroote Centre for Medicinal Cannabis Research do?
9:20 What are the risks and benefits of medical cannabis for older adults?
11:10 What is the evidence for common medical applications of cannabis?
15: 36 What are the risks and harms of cannabis?
17:16 What does the research say about medicinal cannabis for chronic pain?
28:28 Can cannabis help those with Parkinson’s disease, multiple sclerosis, or other neurological conditions?
37:09 What is known about the long-term effects of medical cannabis use?
46:22 Can medical cannabis help with anxiety or post-traumatic stress disorder?
Want to test your knowledge? After watching this video take this quick 5-question quiz.
Dr. James MacKillop is the Director of the Michael G. DeGroote Centre for Medicinal Cannabis Research and the Director of the Peter Boris Centre for Addictions Research. James is a Professor in the Department of Psychiatry & Behavioural Neurosciences. His research interests include the nature and treatment of substance use disorders and related conditions.
Author Details
Jason Busse
Dr. Jason Busse is the Associate Director of the Michael G. DeGroote Centre for Medicinal Cannabis Research and is a Professor in the Departments of Anesthesia and Health Research Methods, Evidence and Impact at McMaster University. His research interests include chronic pain and evidence-based clinical practice.
Author Details
Anthony Levinson
Dr. Anthony J. Levinson is a Professor at McMaster University and holds the John R. Evans Chair in Health Sciences Educational Research and Instructional Development. One of the co-leaders of the McMaster Optimal Aging Portal, Dr. Levinson is also a psychiatrist with a special interest in medical psychiatry, neuropsychiatry, and preventive psychiatry. His area of research interest includes online learning to improve healthcare provider and patient education.
References
Michael G. DeGroote Centre for Medicinal Cannabis Research. Accessed October 31, 2022. https://cannabisresearch.mcmaster.ca/ Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618
Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. Published online September 8, 2021:n2040. doi:10.1136/bmj.n2040
Turna J, Patterson B, van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34(11):1006-1017. doi:10.1002/da.22664
Tibbo PG, McKee KA, Meyer JH, et al. Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness? The Canadian Journal of Psychiatry. 2021;66(2):185-194. doi:10.1177/0706743720945525
Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. The use of cannabinoids for sleep: A critical review on clinical trials. Exp Clin Psychopharmacol. 2019;27(4):383-401. doi:10.1037/pha0000285
AminiLari M, Wang L, Neumark S, et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep. 2022;45(2). doi:10.1093/sleep/zsab234
Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. Published online September 8, 2021:n1034. doi:10.1136/bmj.n1034
Peball M, Krismer F, Knaus H, et al. Non‐Motor Symptoms in Parkinson’s Disease are Reduced by Nabilone. Ann Neurol. 2020;88(4):712-722. doi:10.1002/ana.25864
Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588. doi:10.1016/j.psyneuen.2014.11.002
DISCLAIMER: These summaries are provided for informational purposes only. They are not a substitute for advice from your own health care professional. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the McMaster Optimal Aging Portal (info@mcmasteroptimalaging.org).
_jpg.jpg?sfvrsn=bcb0dd6_2)
